臨床眼科67巻12号

2013年11月発行

特集 抗VEGF薬をどう使う？

PDTとの併用療法

著者： 森實祐基¹ 白神史雄¹

所属機関： ¹岡山大学大学院医歯薬総合研究科眼科学分野

ページ範囲：P.1850 - P.1859

はじめに

　現在，加齢黄斑変性（age-related macular degeneration：AMD）に対する治療法の第一選択は抗血管内皮増殖因子（vascular endothelial growth factor：VEGF）薬である。しかし，抗VEGF薬に抵抗する症例が少なからず存在し，そのために治療回数や診察回数が急激に増加している。このような治療および診察回数の増加は，治療に伴う眼合併症や全身副作用のリスク，そして患者の経済的負担の増大につながり，医学的にも医療経済的にも重大な問題である。そのため，抗VEGF薬の治療回数を減らす目的で他の治療法との併用療法が試みられてきた。

　現在，抗VEGF薬と併用する治療法，薬剤としては主に光線力学療法（photodynamic therapy：PDT）とステロイドが挙げられる。本稿ではそのなかでも特に，抗VEGF薬とPDTの併用療法の現状について，近年のランダム化比較試験の結果をもとに解説する。

参考文献

1）Japanese Age-Related Macular Degeneration Trial（JAT）Study Group：Japanese age-related macular degeneration trial：1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. AJOPHT　136：1049-1061, 2003

2）Japanese Age-Related Macular Degeneration Trial（JAT）Study Group：Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration（AMD）：results of the Japanese AMD Trial（JAT）extension. Jpn J Ophthalmol　52：99-107, 2008

3）Tano Y；Ophthalmic PDT Study Group：Guidelines for PDT in Japan. Ophthalmology　115：585-585, e6, 2008

4）Brown DM, Kaiser PK, Michels M et al：Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med　355：1432-1444, 2006

5）Isola V, Pece A, Parodi MB：Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization. AJOPHT　142：680-683, 2006

6）Isola V, Pece A, Brancato R：Circulatory changes in the choroidal vasculature after verteporfin-based photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina　24：618-620, 2004

7）Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C et al：Influence of photodynamic therapy on expression of vascular endothelial growth factor（VEGF）, VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci　44：4473-4480, 2003

8）Goldstein M, Heilweil G, Barak A et al：Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye（Lond）　19：1315-1324, 2005

9）Hirami Y, Tsujikawa A, Otani A et al：Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina　27：335-341, 2007

10）Tomita K, Tsujikawa A, Yamashiro K et al：Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. AJOPHT　153：68-80, e1, 2012

11）Cho M, Barbazetto IA, Freund KB：Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol　148：70-8, e1, 2009

12）Stangos AN, Gandhi JS, Nair-Sahni J et al：Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol　150：666-673, 2010

13）Kaiser PK, Boyer DS, Cruess AF et al：Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration：twelve-month results of the DENALI study. Ophthalmology　119：1001-1010, 2012

14）Larsen M, Schmidt-Erfurth U, Lanzetta P et al：Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration：twelve-month MONT BLANC study results. Ophthalmology　119：992-1000, 2012

15）Miller JW. Treatment of age-related macular degeneration：beyond VEGF. Jpn J Ophthalmol　54：523-528, 2010

16）Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin：one-year results of 2 randomized clinical trials―TAP report. Treatment of age-related macular degeneration with photodynamic therapy（TAP）Study Group. Arch Ophthalmol　117：1329-1345, 1999

17）Blinder KJ, Bradley S, Bressler NM et al：Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration：TAP and VIP report no. 1. AJOPHT　136：407-418, 2003

18）Tsuchiya D, Yamamoto T, Kawasaki R et al：Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina　29：960-965, 2009

19）Akaza E, Mori R, Yuzawa M：Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina　28：717-722, 2008

20）Gomi F, Ohji M, Sayanagi K et al：One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology　115：141-146, 2008

21）Silva RM, Figueira J, Cachulo ML et al：Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol　243：973-979, 2005

22）Chan WM, Lam DS, Lai TY et al：Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy：one-year results of a prospective case series. OPHTHA　111：1576-1584, 2004

23）Quaranta M, Mauget-Faÿsse M, Coscas G：Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. AJOPHT　134：277-280, 2002

24）Spaide RF, Donsoff I, Lam DL et al：Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina　22：529-535, 2002

25）Gomi F, Sawa M, Sakaguchi H et al：Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol　92：70-73, 2008

26）Kokame GT, Yeung L, Lai JC：Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy：6-month results. Br J Ophthalmol　94：297-301, 2010

27）Lai TY, Chan WM, Liu DT et al：Intravitreal bevacizumab（Avastin）with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol　92：661-666, 2008

28）Cheng CK, Peng CH, Chang CK et al：One-year outcomes of intravitreal bevacizumab（avastin）therapy for polypoidal choroidal vasculopathy. Retina　31：846-856, 2011

29）Koh A, Lee WK, Chen LJ et al：EVEREST study：efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina　32：1453-1464, 2012

30）Joeres S, Heussen FM, Treziak T et al：Bevacizumab（Avastin）treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol　245：1597-1602, 2007

31）Saito M, Shiragami C, Shiraga F et al：Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol　149：472-81, e1, 2010

32）Shirakata Y, Shiragami C, Yamashita A et al：One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol　56：599-607, 2012

33）Saito M, Shiragami C, Shiraga F et al：Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol　146：935-41, e1, 2008

34）Seidel G, Werner C, Weger M et al：Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation. Acta Ophthalmologica 2013［Epub ahead of print］

35）Saito M, Iida T, Kano M：Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proli-feration. Jpn J Ophthalmol　57：211-220, 2013

36）Viola F, Mapelli C, Villani E et al：Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Eye（Lond）　24：1344-1351, 2010

37）Lo Giudice G, Gismondi M, De Belvis V et al：Single-session photodynamic therapy combined with intravitreal bevacizumab for retinal angiomatous proliferation. Retina　29：949-955, 2009

38）髙橋寛二・小椋祐一郎・石橋達朗・他：加齢黄斑変性の治療指針．日眼会誌　116：12：1150-1155，2012

39）Yamashita A, Shiraga F, Shiragami C et al：One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol　149：465-71, e1, 2010

40）Yamashita A, Shiraga F, Shiragami C et al：Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol　155：96-102, e1, 2013

41）Nakano S, Honda S, Oh H et al：Effect of photodynamic therapy（PDT）, posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation. OPTH　6：277-282, 2012

42）Sawa M, Iwata E, Ishikawa K et al：Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular dege-neration. Jpn J Ophthalmol　56：470-475, 2012

43）永井由巳：PDT-薬剤併用療法の利点．眼科手術　22：293-297，2009

44）白神千恵子：PDT-薬剤併用療法の実際（方法）．眼科手術　22：299-304，2009